Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 12/20 | 0.39 |
| ▸ | HTR2B | P41595 | 11/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985939 | 0.77 | HRH4 (0.42) | HRH3HRH4HTR2CHTR2BHTR2A | |
| SCHEMBL27429839 | 0.74 | HRH3 (0.37) | HRH3HRH4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL92726 | 0.71 | HRH3 (0.53) | HRH3HRH4HTR2CHTR2ASLC6A4 | |
| SCHEMBL38661680 | 0.71 | HRH3 (0.53) | HRH3HRH4HTR2CHTR2ASLC6A4 | |
| SCHEMBL7385487 | 0.68 | PARP1 (0.41) | HRH3HRH4 | |
| SCHEMBL2467564 | 0.67 | HTR2A (0.49) | HTR2CHTR2A | |
| SCHEMBL13162089 | 0.66 | HRH3 (0.42) | HRH3HRH4 | |
| SCHEMBL9704857 | 0.66 | DRD2 (0.50) | HTR2ASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL13634946 | 0.66 | CHRNB2 (0.50) | HRH3HTR2CHTR2A | |
| SCHEMBL1237690 | 0.65 | MAOB (0.49) | HRH3HRH4HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841685-B2 | Methods for making bis-heterocyclic alkaloids | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20030232988-A1 | Methods for making bis-heterocyclic alkaloids | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY,THE | 2003-12-18 | — | — | US | disclosed |
| WO-2001094310-A1 | METHODS FOR MAKING BIS-HETEROCYCLIC ALKALOIDS | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232988-A1 | Methods for making bis-heterocyclic alkaloids | CIAPIN1, AAAS, MDN1 | HRH3 1423/4885HRH4 1345/4885HTR2C 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.